| Primary |
| Hyperparathyroidism Secondary |
53.2% |
| Drug Use For Unknown Indication |
16.4% |
| Hyperparathyroidism Primary |
8.1% |
| Product Used For Unknown Indication |
7.5% |
| Hypertension |
2.6% |
| Pre-existing Disease |
2.4% |
| Anaemia |
1.3% |
| Hyperparathyroidism |
1.1% |
| Parathyroid Tumour Malignant |
1.1% |
| Renal Failure Chronic |
1.0% |
| Hypercalcaemia |
0.8% |
| Hyperphosphataemia |
0.8% |
| Blood Pressure |
0.7% |
| Acne |
0.5% |
| Cardiac Disorder |
0.5% |
| Dialysis |
0.5% |
| Gastritis |
0.5% |
| Blood Cholesterol Abnormal |
0.3% |
| Blood Cholesterol Increased |
0.3% |
| Constipation |
0.3% |
|
| Vomiting |
21.1% |
| Weight Decreased |
6.9% |
| Hypocalcaemia |
6.3% |
| Myalgia |
5.1% |
| Hypotension |
4.6% |
| Nausea |
4.6% |
| Pancreatitis |
4.6% |
| Myocardial Infarction |
4.0% |
| Pruritus |
4.0% |
| Renal Failure |
4.0% |
| Renal Impairment |
4.0% |
| Status Epilepticus |
4.0% |
| Tremor |
4.0% |
| Convulsion |
3.4% |
| Death |
3.4% |
| Gamma-glutamyltransferase Increased |
3.4% |
| Paraesthesia |
3.4% |
| Weight Increased |
3.4% |
| Diarrhoea |
2.9% |
| Hypercalcaemia |
2.9% |
|
| Secondary |
| Hyperparathyroidism Secondary |
25.8% |
| Drug Use For Unknown Indication |
20.1% |
| Product Used For Unknown Indication |
13.4% |
| Hypertension |
10.8% |
| Renal Impairment |
4.1% |
| Renal Disorder |
3.1% |
| Anaemia |
2.6% |
| Atrial Tachycardia |
2.6% |
| Dialysis |
2.6% |
| General Anaesthesia |
2.1% |
| Anaesthesia |
1.5% |
| Hyperphosphataemia |
1.5% |
| Osteoporosis |
1.5% |
| Prophylaxis |
1.5% |
| Renal Failure Chronic |
1.5% |
| Antibiotic Therapy |
1.0% |
| Anticoagulant Therapy |
1.0% |
| Cerebral Infarction |
1.0% |
| Coronary Artery Disease |
1.0% |
| Dyslipidaemia |
1.0% |
|
| Proteinuria |
21.5% |
| Intravascular Haemolysis |
12.3% |
| Venous Stenosis |
7.7% |
| Multi-organ Failure |
6.2% |
| Myalgia |
6.2% |
| Osteonecrosis |
4.6% |
| Hiatus Hernia |
3.1% |
| Hypocalcaemia |
3.1% |
| Lymphoedema |
3.1% |
| Lymphopenia |
3.1% |
| Melaena |
3.1% |
| Muscle Spasms |
3.1% |
| Neutropenia |
3.1% |
| Premature Delivery |
3.1% |
| Sepsis |
3.1% |
| Transaminases Increased |
3.1% |
| Ventricular Arrhythmia |
3.1% |
| Vitamin A Deficiency |
3.1% |
| Weight Increased |
3.1% |
| Abortion Induced |
1.5% |
|
| Concomitant |
| Drug Use For Unknown Indication |
40.0% |
| Product Used For Unknown Indication |
23.9% |
| Hyperparathyroidism Secondary |
8.5% |
| Hypertension |
4.4% |
| Anaemia |
2.9% |
| Hyperphosphataemia |
2.6% |
| Renal Failure Chronic |
2.2% |
| Hyperparathyroidism |
2.1% |
| Peritoneal Dialysis |
1.6% |
| Renal Failure |
1.6% |
| Depression |
1.5% |
| Pain |
1.4% |
| Renal Transplant |
1.2% |
| Prophylaxis |
1.1% |
| Thrombosis Prophylaxis |
1.0% |
| Coronary Artery Disease |
0.9% |
| Prophylaxis Against Gastrointestinal Ulcer |
0.9% |
| Vitamin Supplementation |
0.8% |
| Dialysis |
0.7% |
| Blood Phosphorus Increased |
0.6% |
|
| Pyrexia |
9.2% |
| Hyperphosphataemia |
6.9% |
| Peritoneal Cloudy Effluent |
6.9% |
| Respiratory Tract Infection |
5.7% |
| Sepsis |
5.7% |
| Skin Ulcer |
5.7% |
| Transplant Rejection |
5.7% |
| Vomiting |
5.7% |
| Cardiac Arrest |
4.6% |
| Convulsion |
4.6% |
| Pruritus |
4.6% |
| Shunt Thrombosis |
4.6% |
| Therapeutic Response Decreased |
4.6% |
| Toxic Epidermal Necrolysis |
4.6% |
| Aplasia Pure Red Cell |
3.4% |
| Femur Fracture |
3.4% |
| Haematochezia |
3.4% |
| Hospitalisation |
3.4% |
| Hypertension |
3.4% |
| Osteonecrosis |
3.4% |
|
| Interacting |
| Hyperparathyroidism Secondary |
35.7% |
| Acne |
10.7% |
| Coronary Artery Disease |
7.1% |
| Hypertension |
7.1% |
| Pain |
7.1% |
| Dyslipidaemia |
3.6% |
| Hyperparathyroidism |
3.6% |
| Nausea |
3.6% |
| Osteoporosis |
3.6% |
| Prophylaxis Against Gastrointestinal Ulcer |
3.6% |
| Renal Failure |
3.6% |
| Restless Legs Syndrome |
3.6% |
| Type 2 Diabetes Mellitus |
3.6% |
| Vitamin Supplementation |
3.6% |
|
| Proteinuria |
72.7% |
| Drug Interaction |
9.1% |
| Supraventricular Tachycardia |
9.1% |
| Transaminases Increased |
9.1% |
|
